Narrative
Research at the University of Manchester (UoM) has changed the landscape of medical care and research in fungal infections internationally. The impacts include: the world’s first commercialised molecular diagnostic products for aspergillosis and Pneumocystis pneumonia (£10m investment); pivotal contributions to the preclinical development (£35m investment), clinical developments and registrations of 3 new antifungals with combined market share of ~$2 billion; one (voriconazole, 2012 sales >$750m worldwide) now first line therapy for invasive aspergillosis with improved survival of 15-20%; and internationally validated methods to detect azole resistance in Aspergillus (an emerging problem partly related to environmental spraying of azole fungicides for crop protection).| Impact date | 2014 |
|---|---|
| Category of impact | Health impacts |
| Impact level | Benefit |
Documents & Links
Related content
-
Research output
-
Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus
Research output: Contribution to journal › Article › peer-review
-
Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure
Research output: Contribution to journal › Article › peer-review
-
High-frequency triazole resistance found in nonculturable aspergillus fumigatus from lungs of patients with chronic fungal disease
Research output: Contribution to journal › Article › peer-review
-
Chronic Cavitary and Fibrosing Pulmonary and Pleural Aspergillosis: Case Series, Proposed Nomenclature Change, and Review
Research output: Contribution to journal › Article › peer-review
-
Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study
Research output: Contribution to journal › Article › peer-review
-
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
Research output: Contribution to journal › Article › peer-review
-
Impacts
-
Transforming patient outcome of pulmonary aspergillosis with better and faster diagnosis and therapy
Impact: Health and wellbeing, Economic
-
Defining global antifungal azole resistance in Aspergillus – enhancing diagnostics and driving drug discovery
Impact: Health and wellbeing, Policy, Economic
-
Successfully tackling serious fungal diseases to transform global population health
Impact: Health and wellbeing